Morphinsulfat Gry (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Morphinsulfat Gry, is an opioid analgesic presented as an injectable solution for intravenous use. It treats moderate to severe acute pain, postoperative pain, cancer pain, and severe trauma pain in adult patients.\n\nGNH India supplies Morphinsulfat Gry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Morphine Sulfate is an opioid analgesic used to manage pain across several clinical settings.\n\n- Moderate to severe acute pain: provides rapid analgesia for intense pain episodes.\n- Postoperative pain: controls pain following surgical procedures.\n- Cancer pain: alleviates persistent pain associated with malignant disease.\n- Severe trauma pain: offers potent relief for injuries causing high‑intensity pain.

Morphine Sulfate may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Constipation\n- Drowsiness or sedation\n- Dry mouth\n- Sweating\n- Itching or pruritus\n\nSerious or Rare Side Effects:\n- Respiratory depression\n- Severe hypotension\n- Bradycardia\n- Allergic reactions including anaphylaxis\n- Urinary retention\n- Neurotoxicity with high doses

When using Morphine Sulfate, clinicians should consider several safety measures.\n\n- Assess pain level: determine appropriate analgesic intensity.\n- Monitor respiratory function: watch for signs of depression.\n- Adjust for renal or hepatic impairment: dose may need reduction.\n- Avoid use in patients with known hypersensitivity to opioids.\n- Use caution in the elderly: increased sensitivity to side effects.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Morphine Sulfate can interact with other medications, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression.\n- MAO inhibitors: risk of severe opioid toxicity.\n- CYP3A4 inhibitors (e.g., ketoconazole) can increase morphine levels.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin) may reduce analgesic effect.\n- Anticholinergic agents: may worsen constipation.\n- Diuretics: can enhance hypotensive effects.